• 1
    Ferrari MD. Migraine. Lancet 1998; 351: 104351.
  • 2
    Rasmussen BK. Epidemiology and socio-economic impact of headache. Cephalalgia 1999; 19(Suppl. 25): 203.
  • 3
    White AR, Resch KL, Ernst E. Complementary medicine: use and attitudes among GPs. Fam Pract 1997; 14: 3026.
  • 4
    Wadlow G, Peringer E. Retrospective survey of patients of practitioners of traditional Chinese acupuncture in the UK. Complement Ther Med 1996; 4: 17.
  • 5
    Hayhoe S, Box H. A questionnaire on medical acupuncture practice. Acup Med 1997; 15: 969.
  • 6
    Melchart D, Linde K, Fischer P et al. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials. Cephalalgia 1999; 19: 77986.
  • 7
    Tfelt-Hansen P. How to define the best efficacy parameters for migraine. Cephalalgia 1997; 17(Suppl. 17): 68.
  • 8
    Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 5328.
  • 9
    Goebel H, Schmerzmessung. Theorie-Methodik-Anwendung bei Kopfschmerz. Stuttgart: Gustav Fischer Verlag, 1992; 769.
  • 10
    Heller O. Theorie und Praxis des Verfahrens der Kategorienunterteilung (KU). In: HellerO ed. Forschungsbericht 1981. Würzburger Psychologisches Institut Würzburg, 1982.
  • 11
    Marcus R. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 65560.
  • 12
    Wellek S. Statistische Methoden zum Nachweis von Äquivalenz. Stuttgart: Gustav Fischer Verlag, 1994.
  • 13
    Vincent C, Lewith G. Placebo controls for acupuncture studies. J Roy Soc Med 1995; 88: 199202.
  • 14
    Streitberger K, Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet 1998; 352: 3645.
  • 15
    Schoenen J, Bulcke J, Caekebeke J et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994; 14: 5563.
  • 16
    Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 1804.
  • 17
    Göbel H, Heinze A, Stolze H, Heinze-Kuhn K, Lindner V. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia 1999; 19: 67683.
  • 18
    Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache 2000; 40: 7927.
  • 19
    Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatrpitan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22: 103548.
  • 20
    Henry P, D'Allens H. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993; 33: 4325.
  • 21
    Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 28315.
  • 22
    MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 4015.
  • 23
    Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR. A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild or moderate hypertension. Cephalalgia 1999; 19: 959.
  • 24
    Akpunonu BE, Mutgi AB, Federman DJ et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995; 25: 4649.
  • 25
    Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double blind, double-dummy, randomized, multicenter, parallel-group study. Cephalalgia 1999; 19: 5818.